BioCentury | Jul 20, 2015
Clinical News

TSR-011: Interim Phase I/IIa data

...Additional interim data from an open-label Phase I/IIa in patients with solid tumors showed that TSR-011...
...5 ALK inhibitor-naive patients and in 3 of 6 patients who progressed after Xalkori crizotinib. TSR-011...
...TSR-011 every 12 hours. The trial is enrolling an expansion cohort to receive 40 mg TSR-011...
BioCentury | Sep 15, 2014
Company News

Paradigm, Tesaro deal

...samples from clinical trials to predict which patients may be sensitive or resistant to Tesaro's TSR-011...
...to make a decision about next steps for TSR-011. Tesaro has exclusive, worldwide rights to TSR-011...
BioCentury | Mar 17, 2014
Finance

Tesaro's low down payment

...combination with Tesaro's niraparib and TSR-011 this year. Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor. TSR-011...
BioCentury | Mar 17, 2014
Company News

Anaptys, Tesaro deal

...antibodies with its TSR-011 and niraparib in addition to other antitumor agents with complementary mechanisms. TSR-011...
BioCentury | Nov 21, 2013
Distillery Therapeutics

Indication: Cancer

...Amgen Inc. and Tesaro Inc. have the dual TrkA and anaplastic lymphoma kinase (ALK) inhibitor TSR-011...
BioCentury | Oct 28, 2013
Clinical News

TSR-011: Preliminary Phase I/IIa data

...dose-escalation Phase I portion of an open-label Phase I/IIa in 17 evaluable patients showed that TSR-011...
...3 patients with ALK-positive non-small cell lung cancer (NSCLC) who progressed on prior crizotinib treatment, TSR-011...
...as measured by RECIST criteria, 1 investigator-assessed partial response and 1 case of stable disease. TSR-011...
Items per page:
1 - 6 of 6